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Abstract
Background: Development of therapies for patients with BRCA1 mutations has been hampered
by lack of readily available in vitro and in vivo models. We recently showed that transplantation of
transgenic mammary tumors as cell suspensions into naïve recipients generates reproducible
tumors with remarkable stability of gene expression profile. We examined the expression profiles
of original and serially transplanted mammary tumors from Brca1 deficient mice, and tumor derived
cell lines to validate their use for preclinical testing and studies of tumor biology.
Methods: Original tumors, serially transplanted and multiple cell lines derived from Brca1
mammary tumors were characterized by morphology, gene and protein expression, and cell
surface markers.
Results: Gene expression among Brca1 tumors showed more heterogeneity than among
previously characterized tumors from MMTV-PyMT and -Wnt1 models. Gene expression data
segregated Brca1 tumors into 3 distinct types: basal, mixed luminal, and tumors with epithelial-to-
mesenchymal transition (EMT). Serial transplantation of individual tumors and multiple cell lines
derived from the original tumors recapitulated the molecular characteristics of each tumor of
origin. One tumor had distinct features of EMT and gave rise to cell lines that contained a distinct
CD44+/CD24-/low population that may correlate with human breast cancer stem cells.
Conclusion: Although individual tumors expanded by transplantation maintain the genomic profile
of the original tumors, the heterogeneity among Brca1 tumors limits the extent of their use for
preclinical testing. However, cell lines offer a robust material for understanding tumor biology and
response to therapies driven by BRCA1 deficiency.
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Breast cancer is the most common neoplastic disease in
women and affects approximately 1 out of 10 females.
Human breast cancer is a heterogeneous disease with var-
ied clinical course [1,2]. Up to 5% breast cancer cases are
attributable to inherited mutations in the BRCA1 or
BRCA2 genes [3]. Inherited mutations of BRCA1 (chro-
mosome 17q21) have been linked to increased risk for
breast and ovarian cancers [4]. The BRCA1 tumor suppres-
sor plays a major role in DNA damage, signaling, repair
and cell cycle control. BRCA1 is also a co-regulator of ster-
oid hormone receptors and modifies steroid hormone
action [5]. Carriers of the mutant gene also have signifi-
cantly higher risk for developing other tumor types,
including ovarian, uterine, cervical, and prostate cancers
[6]. Breast cancer patients with BRCA1 mutations are
more likely to be estrogen receptor (ER) and HER-2 nega-
tive, and have mutant or deleted p53 [7]. In spite of
advances in detection and clinical management for
patients with familiar BRCA1 mutant breast cancer, there
has been no significant improvement in therapies and
overall survival for these patients [8].
Microarray analysis has been useful in identifying gene
expression signatures that characterize qualities important
for biological and clinical classification [9,10]. Pheno-
typic characterization and microarray profiling of breast
tumors reveals distinct subtypes of breast carcinoma that
are associated with survival. Five major groups of invasive
breast carcinomas have been identified: luminal A, lumi-
nal B, HER2 +/ ER -, basal-like, and normal breast-like
[10]. The basal-like tumors are typically ER and HER2-
negative, have high proliferative rate, and typically show a
poor clinical outcome [10].
BRCA1 and BRCA2 are essential for maintenance of
genomic integrity by promoting repair of double-stranded
DNA breaks. Following DNA damage, BRCA1 is phospho-
rylated by the ATM/ATR kinases and recruits multiple fac-
tors to the break site that actively participate in repair [11].
BRCA1 associates and co-localizes with RAD51 nuclear
foci in mitotic cells along with BRCA2 and BARD1, a
BRCA1 binding protein [12]. BRCA1 deficiency leads to
impaired double-strand break repair and to enhanced sen-
sitivity to ionizing radiation and genomic instability
[11,13]. However, only limited studies are reported using
human cells, most of them derived from analysis of one
human cell line that is null for BRCA1, HCC1937 [14].
Although BRCA1 replacement increased the resistance to
Vinorelbine and Cisplatin, it did not change sensitivity to
other agents, such as Docetaxel [14] suggesting that mul-
tiple mechanisms may be associated with drug resistance
in this cell line.
Studies of tumor biology and development of novel ther-
apies for tumors associated with BRCA1 deficiency are
hampered by the lack of readily available material for in
vitro and in vivo studies. Genetically engineered mouse
tumors are an excellent tool for studying cancer biology
and can potentially improve preclinical studies. Develop-
ment of multiple mouse models with deletion or muta-
tions in Brca1 targeted to the mammary gland has
provided an opportunity to examine the biology and ther-
apeutic implications of BRCA1 loss in breast cancer [15]
and some studies find similarities between the mouse and
human tumors [11,16,17]. In particular, correlations with
human basal-like tumors have been reported in Brca1
mouse models [17,18]. However, using Brca1 mouse
mammary models for preclinical development has been
limited due to complicated breeding schemes, variable
penetrance, and prolonged latency of tumor development
[19]. In spite of increased penetrance when mice hetero-
zygous for the Tp53 tumor suppressor are crossed with
mice harboring mutant Brca1, these mice develop mam-
mary tumors in over one year, at which time development
of lymphomas, which is characteristic of p53-deficient
background, also compromises animal survival [20].
Expansion of Brca1 deficient mammary tumors by trans-
plantation is a useful alternative for generating sufficient
material for studying Brca1-associated tumorigenesis. The
purpose of our study was to harvest, expand in vivo, and
characterize tumors and cell lines derived from Brca1
mammary tumors. The original and transplanted tumors
as well as well-characterized cell lines derived from origi-
nal tumors provide the necessary tools for studying the
biology of Brca1-deficient tumors, identification of puta-
tive cancer stem cells, and development of novel therapies
to improve clinical outcome.
Materials and methods
Tumors and serial transplantations of cell suspensions
All studies were conducted in an AAALAC accredited facil-
ity in compliance with the PHS Guidelines for the Care and
Use of Animals in Research. Naïve 6-to-8 week old female
scid/NCr (BALBc) mice from the NCI Animal Production
Program (Frederick, MD) were used as transplant recipi-
ents. Autoclaved feed and hyper-chlorinated water were
provided ad libitum. The Brca1Co/CoΔexon11, p53+/-, MMTV-
Cre mouse mammary tumors [21] were dissected and cell
suspensions prepared as described by Varticovski and
coworkers [22]. In summary, tumors were excised, dis-
sected, mechanically dissociated and forced through a 40
uM mesh. Viable cells were either frozen in freeze down
media, or plated at low density in 100 or 150 mm plates
in RPMI supplemented with Pen/Strep, glutamine, and
2% FCS for selection of cell lines. Non-adherent cells were
removed after 48 hours and surviving clones were isolated
using cloning cylinders. For implantation of cell suspen-Page 2 of 12
(page number not for citation purposes)
Molecular Cancer 2008, 7:29 http://www.molecular-cancer.com/content/7/1/29sions into naïve recipients, the mouse fat pad #4 of SCID
mice was visualized through a small skin incision just
anterior to the rear leg, and one million cells were injected
in 50μ l of RPMI-1640. The incision was closed with a
sterile wound clip, which was removed in 7 days.
Tumor size was determined biweekly using caliper meas-
urements (millimeters) in two perpendicular dimensions
(length and width). Tumor weights (milligrams) were cal-
culated using the formula for a prolate ellipsoid and
assuming a specific gravity of 1.0 g/cm3 [23]. Mice were
killed when tumors reached an approximate 1 g of wet
weight. Tumors were divided into the following frag-
ments: a portion was used to prepare cell suspensions and
further passages in vivo, the remaining was frozen or fixed
in 10% neutral-buffered formalin.
Generation and genotyping of Brca1 tumor cell lines
Cells derived from Brca1 mammary tumors were grown at
37°C in 5% CO2 in RPMI-1640 media supplemented with
increasing concentrations of FBS up to 10%, pen/strep,
and glutamine. Over 40 clones were isolated. Sixteen cell
lines were developed from 5 original primary tumors and
maintained in culture for up to 50 passages in RPMI1640
supplemented with 10%FCS.
Brca1 primary tumors and cell lines were genotyped as
described by PCR amplification of sequences specific for
the null Brca1 allele [20], conditional Brca1 (Brca1Co/Co)
allele [13,21], wild-type p53 allele [20], and CRE [20,24].
RNA isolation, microarray hybridization and data analysis
Total RNA was isolated from 5 spontaneous (original, 0)
Brca1 mammary tumors, 4 tumors from first-passage
transplantation into naïve recipients (first-passage, 1), 3
tumors from second-passage transplantation into naïve
recipients (second-passage, 2), and 7 representative origi-
nal tumor-derived cell lines. Normal virgin mammary
glands from three #4 glands of 6–8 wk old C57Bl6 or
SCID mice were included in the microarray analysis. Total
RNA was isolated using TRIzol reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer's instruc-
tions, followed by DNAse treatment and RNA clean-up
(RNeasy Mini Kit, QIAGEN, Valencia, CA). RNA integrity
was determined using the RNA 6000 Nano LabChip Kit
on Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA).
RNA was amplified and hybridized overnight to the Agi-
lent Mouse Oligo Microarrays 22 K (G4121AorB) against
a common reference total RNA [17]. The co-hybridized
samples and reference RNA were washed and scanned on
an Axon GenePix 4000B scanner (Molecular Devices, Sun-
nyvale, CA), analyzed using GenePix 4.1 software, and
uploaded to the UNC microarray database where Lowess
normalization was performed [25]. Genes were filtered by
requiring the Lowess-normalized intensity values in both
channels to be > 30. The log2 ratio of Cy5/Cy3 was then
reported for each gene. Hierarchical clustering and Gene
Set Expression Comparison were performed using BRB
Array Tools software developed by the Biometric Research
Branch of the NCI [26]. Analysis was restricted to probes
that reported values in 75% or more of the samples for
comparative analysis or probes that in addition had a
minimum 2.5 – fold expression change in either direction
from the median value in at least 20% of samples, for hier-
archical clustering (defined as most variable genes).
A comparative analysis of previously published microar-
ray expression data of Brca1-deficient tumors on the same
array platform [17] was performed using Gene Cluster
3.0. To this end, we compared gene expression from 22
arrays encompassing the 5 original Brca1 tumors from our
study, with 7 tumors from Brca1+/-, p53+/- irradiated (IR,
Kohler) mice, and 10 tumors from Brca1Co/Co, p53+/-,
MMTV-Cre (Furth) from a previous study [17]. Genes
[20,988] were filtered for 80% present (to remove genes
that have missing values in greater than 20% of the arrays)
and Standard Deviation (SD Gene Vector) >= 1.5 (to
remove genes that have standard deviations of observed
values less than 1.5, thus selecting for more variable genes
across experiments). This filter yielded 339 genes that
were used for Hierarchical Clustering. The dendrograms
were visualized with Java TreeView.
Analysis of cell surface markers
Cells from each cell line were grown to 70% confluence,
scraped or trypsinized, stained with PE Anti-mouse CD44
(BD Pharmingen, San Jose, CA), APC Anti-mouse CD24
(Biolegend, San Diego, CA), FITC Anti-mouse CD44
(Southern Biotech, Birmingham, AL), or APC Anti-mouse
CD117 (Biolegend). Rat IgG (CHEMICON, Billerica, MA)
was used as the isotype control according to manufac-
turer's instructions. For analysis of Cytokeratins, cells were
washed in ice-cold PBS, fixed in 70% ethanol, and stained
with either Cytokeratin 5 (Covance, Berkeley, CA) or
Cytokeratin 18 (Abcam, Cambridge, MA), and counter-
stained with Alexa 488-conjugated anti-rabbit or anti-
mouse IgG, respectively. Cells were analyzed by flow
cytometry using FACScalibur or LSR II (BD Biosciences,
San Jose, CA). Data were collected with Cell Quest Pro
software (BD) from no fewer than 10,000 cells and FACS-
DiVa software (BD) from no fewer than 30,000 cells,
respectively.
Immunohistochemistry
Paraffin sections of original and transplanted tumors were
stained for H&E for histological analysis. Histology of
original tumors was compared to transplanted tumors
derived from cell suspensions. Immunofluorescent stain-
ing was performed for smooth muscle actin (SMA) using
mouse A2537 antibody (Sigma, St Louis, MO) at 1:1000Page 3 of 12
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antibody (RDI, Concord, MA) at 1:400 dilution. Slides
were de-paraffinized and hydrated through a series of
xylenes and graded ethanol steps. Heat-mediated epitope
retrieval was performed in boiling citrate buffer (pH 6.0)
for 15 min. Samples were then cooled to room tempera-
ture for 30 min. Secondary antibodies for immunofluo-
rescence were conjugated with Alexa Fluor-488 or -594
fluorophores (1:200, Molecular Probes, Invitrogen,
Carlsbad, CA).
Cell lines were plated in chamber glass slides, allowed to
attach overnight, stained with APC Anti-mouse CD117 (c-
kit) from Biolegend, Cytokeratins 5 and 18, and counter
stained with Alexa 488-conjugated anti-rabbit or anti-
mouse IgG, respectively.
Immunoblot analysis
The analysis of protein levels was performed essentially as
described [27]. Membranes were blocked at room temper-
ature for 1 h I nTBS/0.05% Tween-20 (TBS-T) containing
5% non-fat dry milk (monoclonal antibodies) or 5% BSA
(polyclonal antibodies) and exposed to primary antibod-
ies overnight at 4°C in blocking solution. The following
commercial antibodies were used: Keratin 5 (Covance);
Keratin 18 (Abcam); CD117 (Abgent; San Diego, CA),
p53(S15), PDGF Receptor (Anti-CD140a) (Chemicon),
Vimentin (BD Pharmingen), and Actin (Ab-1) (Oncogene
Research Products, Cambridge, MA). Membranes were
washed twice in TBS-T and incubated with species-specific
HRP-labeled secondary antibodies in TBS-T for 1 h.
Finally, the membranes were washed in TBS-T three times
and the proteins were visualized using ECL Western blot-
ting detection reagents (Amersham, Piscataway, NJ).
Results
Gene expression analysis of Brca1 mammary tumors
The overall similarity of gene expression profiles among
five original Brca1 mammary tumors was assessed by pair-
wise correlations of microarray log-ratios based on 15,781
probes with reported values in at least 75% of samples.
The correlation matrix showed Pearson correlation coeffi-
cients for pairwise comparisons of 0.66–0.82 (Figure 1A).
These correlation coefficients are lower than those
obtained for mouse mammary tumors from MMTV-PyMT
(0.79–0.94) or MMTV-Wnt1 (0.87–0.95) mouse tumors
using a similar analysis [22] (Additional file 1A). In spite
of having a similar size at the time of collection (approxi-
mately 1 gm of wet weight), heterogeneity of Brca1 mam-
mary tumors was also evident upon pathological
examination of morphology, immunohistochemistry,
and immunofluorescence analysis of tumor markers.
Although all tumors were adenocarcinomas, the original
tumor 0_A1 had areas of whorls and clusters of spindle-
shaped tumor cells in a myxomatous stroma, features sug-
gestive of epithelial-to-mesenchymal transition (EMT)
(Additional file 2A). Consistently, this tumor was also
positive for protein expression of a mesenchymal marker,
vimentin (Additional file 2B). No evidence of EMT was
found in any of the four other original tumors. One of the
other tumors was an adenocarcinoma with features of
squamous carcinoma (Additional file 2A).
Comparison of Brca1 tumor expression profiles with other 
previously reported Brca1-deficient mouse mammary 
models
In previous studies [17,28] Brca1 loss was found to give
rise to mammary tumors with a primarily basal-like phe-
notype. Two models with Brca1 deficiency were featured
in a large study that used multiple other mouse mammary
tumor models [17], and included 7 mammary tumors
that arose after irradiation of Brca1+/-, p53+/- mice (desig-
nated Brca1+/-, p53+/- IR-Koller) and 10 tumors from
Brca1Co/Co, p53+/-, MMTV-Cre strain, equivalent to the
tumors used in our study (designated Brca1-Furth). Since
the same array platform and common reference RNA had
been used for those studies, we performed an analysis of
all 22 samples as described in Methods and found 339
that distinguished these samples. Unsupervised Hierarchi-
cal Clustering using these 339 most variable genes (Addi-
tional file 3) separated the tumors in 3 main clusters
(Figure 1B). All seven Brca1+/-, p53+/- IR-Koller and 3/10
Brca1-Furth tumors showed a basal-type phenotype, pre-
viously segregated in Group IV, and characterized by
expression of Keratin 5 [17]. Four of the original Brca1
tumors from our study clustered with those four Brca1-
Furth tumors that had mixed basal and luminal features.
An additional cluster was formed by the original Brca1
tumor A1 from our study and three of Brca1-Furth tumors
previously segregated in Group II tumors of spindloid
morphology [17]. This cluster showed mesenchymal-like
features that included lack of epithelial markers, such as
keratins. Moreover, the pattern of expression of keratins
across all 339 filtered genes further defined separation of
all 22 tumors into the same 3 groups (Figure 1C). Thus,
although the majority of Brca1-deficient tumors are basal-
like, some have mixed basal and luminal characteristics,
and a third group has features consistent with EMT.
Serial transplantation generates tumors with a stable gene 
expression profile
Given the apparent heterogeneity of Brca1 mammary
tumors, we examined the extent to which serial transplan-
tations of individual tumors affect gene expression. Cell
suspension from one original (0_A) tumor was trans-
planted into naïve recipients. Unsupervised Hierarchical
Clustering of 5 original Brca1 mammary tumors (0), 4
first-passage (1) and 3 second-passage (2) tumors from
0_A tumor were performed based on 416 most variable
probes (Additional file 4). This analysis showed that thePage 4 of 12
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Characterization of Brca1 tumors (A) Pearson correlation coefficient matrix for pairwise comparisons of log-ratios among five spontan ous Brca1 tumors, based on 15,781 probes with reported values in at least 75% of samples (missin v lue filter)Figure 1
Characterization of Brca1 tumors (A) Pearson correlation coefficient matrix for pairwise comparisons of log-
ratios among five spontaneous Brca1 tumors, based on 15,781 probes with reported values in at least 75% of 
samples (missing-value filter).(B) Unsupervised Hierarchical Cluster of 5 Brca1, 7 Brca1+/-, p53+/- IR and 10 Brca1Co/Co, 
p53+/-, MMTV-Cre (Furth) mammary tumors based on 339 genes filtered for present values and minimal variability of expression 
(see Materials and Methods). (C) The dendrogram corresponds to the summarized data for expression of keratins 5, 
8,17,18,19 and 23, that were among the 339 genes. The color of each cell represents the relative expression level of each 
gene.(D) Unsupervised Hierarchical Cluster of original (0), first- (1) and second- (2) passage tumors based on the 416 probes 
that in addition to passing intensity and missing-value filters had a minimum 2.5-fold expression change in either direction from 
the median value in at least 20% of samples (Additional file 1).
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Molecular Cancer 2008, 7:29 http://www.molecular-cancer.com/content/7/1/29transplanted tumors segregated into a single branch closer
to the tumor of origin, and further subdivided into two
groups according to passage number (Figure 1D). As sug-
gested by the Pearson correlation analysis, evidence that
all original tumors were heterogeneous was indicated by
the long distance of each sample from the immediate tree
node above. Gene expression differences between 0_A
tumor and the average of gene expression in all trans-
planted tumors showed 76 upregulated and 79 downreg-
ulated genes whose expression changed at least 3-fold
(Additional file 4). However, comparison of gene expres-
sion between the first and second passage tumors showed
no genes with significantly different expression (p = 0.2).
Thus, serial transplantation of Brca1 mammary tumors
resulted in minimal gene expression profile changes.
Because the Brca1 original tumors used for our studies
were generated in mice bred in a mixed strain background
composed mostly of C57Bl6 [21], and cell suspensions
were transplanted into immunosuppressed SCID mice,
we hypothesized that some of the genetic differences
between the original and transplanted tumors could be
associated with differences in the genetic background.
Thus, we re-analyzed tumor samples with normal virgin
mammary glands from C57Bl6 and SCID mice using the
416 most variable probes defined above (Additional file
5). This analysis revealed that several immune response
genes, including Histocompatibility 2, class II antigen A,
alpha (H2-aA), Histocompatibility 2, class II, locus Mb1
(H2-DMb1) and Histocompatibility 2, class II antigen A,
beta 1 (H2-Ab1), as well as Lymphotoxin B (Ltb), and
Interleukin 15 (Il15) were downregulated in both, the
transplants and normal SCID mammary gland as com-
pared to original tumors and normal C57Bl mammary
gland. These data are consistent with immunodeficient
genotype of SCID mice, and confirms that many of the
differences in gene expression between the original and
transplanted tumors are due to differences in genetic
background.
The final analysis between the original and transplanted
tumors showed that several of the upregulated genes in
the transplanted tumors were associated with growth,
metastasis, and cancer stem cells, such as Wnt inhibitory
factor 1 (Wif1), Notch gene homolog 4 (Notch4), Hor-
monally-regulated Neu-associated kinase (Hunk),
Sprouty homolog 1 (Spry1), Twist gene homolog 1
(Twist1), and Aldehyde dehydrogenase 3 family, member
B1 (Aldh3b1). In addition, apoptosis-associated Phorbol-
12-myristate-13-acetate-induced protein 1 (Pmaip1) was
among the genes downregulated in transplanted tumors.
These data are consistent with the accelerated growth
observed in serially transplanted tumors [22].
Expression profiling of cell lines and comparative analysis 
with the tumors of origin
The differences between individual Brca1 tumors
prompted us to generate and characterize multiple cell
lines from each original mammary tumor. To ensure that
all 16 cell lines derived from 5 original tumors were free
of non-mammary cellular components, we genotyped
these cells for Brca1Co and p53 alleles. We confirmed that
all cell lines contained the recombined Brca1Co allele and,
as shown for primary mammary tumors in this model,
lost the wild type p53 allele [20] (Additional file 6).
Microarray expression analysis of 7 representative cell
lines from 3 original Brca1 tumors were compared to the
individual tumors of origin. Cell lines B1.1, B1.2, and
B1.15 were generated from the original tumor 0_B1, and
the cell line RP3 was derived from 0_RP tumor. Cell lines
A1.1, A1.8 and A1.10 were derived from the original
tumor 0_A1. This analysis revealed 1,660 most variable
genes. Unsupervised Hierarchical Clustering of all 12
samples using these 1,660 genes showed that the cell lines
were discriminated from the original tumors (Figure 2A).
However, all cell lines derived from the same tumor clus-
tered together in the same sub-branch of the tree, indicat-
ing that molecular features of the original tumor are
preserved in each set of cell lines derived from that tumor.
Some of the differences in gene expression between origi-
nal tumors and cell lines included downregulation of c-kit
(CD117) and further downregulation Cytokeratins 23,
19, 18, 14, 13 and 8, in cell lines. Vimentin, Platelet-
Derived Growth Factor receptor alpha (Pdgfr α) and beta
(Pdgfr β) were among genes that were upregulated in cell
lines consistent with adaptation to tissue culture condi-
tions.
To further assess the conservation of features from origi-
nal tumors to cell lines, we applied the Gene Set Expres-
sion Comparison tool. This tool analyzes pre-defined
gene sets for differential expression among pre-defined
classes, and indicates which gene set(s) contain more dif-
ferentially expressed genes than expected by chance. A
gene set representing differences in gene expression
between the two original tumors 0_A1 and 0_B1 was gen-
erated that contained 914 probes either up- or down-reg-
ulated by at least 4-fold. This gene set was enriched in
genes that were also differentially expressed among the
cell lines, with high significance (p < 1e-07). Consistently,
Unsupervised Hierarchical Clustering of those original
tumors and cell lines based on the 914 differentially
expressed probes showed that the cell lines segregated
with each tumor of origin (Figure 2B). Genes with differ-
ences in expression that were maintained in the original
0_A1 tumor and in cell lines derived from this tumor as
compared to 0_B1 tumor and its respective cell lines
included loss of CD24a, indicating a possible enrichment
in putative cancer stem cells [29,30]. These data indicatePage 6 of 12
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Characterization of Brca1 cell lines (A) Unsupervised Hierarchical Cluster of original tumors (0) and cell lines using the 1660 probes that in addition to passi g intensity and mi sing-value filters had a minimum 2.5-fold expression cha ge in either direc-tion from the me ian v lue in at least 20% of sa pl s (most variable gen s)Figu e 2
Characterization of Brca1 cell lines (A) Unsupervised Hierarchical Cluster of original tumors (0) and cell lines 
using the 1660 probes that in addition to passing intensity and missing-value filters had a minimum 2.5-fold 
expression change in either direction from the median value in at least 20% of samples (most variable genes). 
(B) Unsupervised Hierarchical Cluster of the original tumors 0_A1 and 0_B1 along with the cell lines derived from them. Clus-
ter was based on the 914 genes reporting at least 4-fold difference in expression ratios between original tumor 0_A1 vs origi-
nal tumor 0_B1. (C) Cell lines were stained with specific fluorescently-conjugated mAb to Cytokeratin 18, Platelet-derived 
growth factor receptor (Pdgfr) α or β, as indicated, in parallel with appropriate isotype control-matched mAb and analyzed by 
flow cytometry. In the histograms shown, the thick black line represents positive staining and the gray filled lines represent the 
isotype control-matched staining. The percent of positive cells after compensation is shown on the upper right of each panel.
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groups of cell lines derived from each one of them are sim-
ilarly different from each other.
Correlation of gene expression profile with protein 
expression
We examined the expression of several gene products in
all cell lines by Flow Cytometry and Western Blot.
Although Cytokeratin 18 was downregulated in all cell
lines by expression profiling, the protein was still detecta-
ble by FACS (Figure 2C) and Western Blot (Additional file
7). Upregulation of Pdgfr α which was detected by micro-
array analysis, was confirmed by FACS (Figure 2C) and
Western blot (Additional file 7), while only a low level of
Pdgfr β protein was detected in some cell lines. Variable
expression of Vimentin and CD117 (c-kit) and a consist-
ent loss of Cytokeratin 5 in all cell lines was observed by
Western blot analysis (Additional file 7) which correlated
with gene expression. Interestingly, cell lines derived from
anterior and posterior tumors differed in expression of
CD117 (c-kit) with protein expression detected only in
cell lines derived from tumors arising in posterior mam-
mary glands (Additional file 8).
Detection of putative cancer stem cell markers in Brca1 
cell lines
Recent studies identified putative human breast cancer
stem cells by CD44+/CD24low cell surface markers that
correspond to normal mammary gland-initiating cells in
the mouse model [29,30]. Because we found a decrease in
CD24a gene expression in the original 0_A1 tumor and in
all cell lines derived from this tumor, we examined
whether these cells contain a distinct CD44+/24-/low pop-
ulation. We performed flow cytometry on multiple cell
lines representative of 0_A1 and all 5 original tumors
using CD44 and CD24 markers (Figure 3A). Remarkably,
the A1.1 cell line which is derived from 0_A1 tumor
showed up to 2.6% CD44+/CD24-/low cells. Analysis of
additional cell lines showed that all cell lines derived from
0_A1 tumor were enriched in CD44+/CD24-/low popula-
tion with 1.32–5% (Figure 3A and data not shown). In
contrast, this cell population was less than 1% in all other
cell lines derived from other tumors (Figure 3C). Specifi-
cally, B1.15 had 0.39%, P2.1 0.60%, and P3.17 0.46% of
CD44+/CD24-/low cells. Thus, enrichment in cells with
markers consistent with human cancer-initiating cells is
preserved in the cell lines derived from the tumor that has
features of EMT. In contrast to small CD44+/24-/low popu-
lation, 50–80% of all cell lines had CD24+ or CD44+/24+
fractions, which makes these markers unlikely to repre-
sent a stem cell-enriched population. There have been no
previous studies implicating CD44+24-/low population as
cancer stem cells in mouse models. Our subsequent stud-
ies confirmed stem cell nature of this population by their
capacity of reconstituting tumors in mice, drug resistance,
and expression of many genes associated with normal
stem cell biology [31].
Discussion
In spite of previously established genomic instability asso-
ciated with Brca1 deficiency [16,27,32-34], transplanta-
tion of original Brca1 mouse mammary tumors into naïve
recipients and generation of cell lines from these tumors
provides a reliable source of material with relatively stable
expression profile. However, due to significant heteroge-
neity among the original tumors, a panel of individual
original tumors will be required for selection of a subset
of tumors with appropriate characteristics and correlation
with human disease.
Transplantation of multiple mouse mammary tumor
models into naïve recipients revealed remarkable stability
of the cancer genome in MMTV-PyMT and -Wnt1 mam-
mary models [22,35]. Similarly, transplantation of a
Brca1 tumor for 2 subsequent passages preserved the
molecular features associated with the tumor of origin.
However, we found significant differences among the
original Brca1 tumors, not previously detected in other
mouse mammary models. Thus, in contrast to other
mouse mammary tumor models in which the genomic
features allow pooling multiple original tumors for
expansion in vivo to provide virtually unlimited starting
material, Brca1 mammary tumors should be analyzed
individually and not pooled. Previous studies found sig-
nificant discrepancies between human disease and some
mouse Brca1 deficient tumor models. These differences
are likely to reflect the innate heterogeneity of Brca1
mouse mammary tumors and analysis of multiple indi-
vidual tumors would be required for selection of appro-
priate tumors that correlate with human disease [28]. In
addition, human BRCA1-associated breast and ovarian
cancers are multifocal and frequently arise in the contral-
ateral breast. Future studies need to be performed to deter-
mine whether differences in gene expression at multiple
sites correlate with the heterogeneity found in the mouse
models and whether these differences correspond to
mixed responses to therapy.
We have previously described that MMTV-PyMT mouse
mammary tumors arise earlier in anterior mammary
gland, have accelerated tumor growth and can be sepa-
rated from posterior tumors by gene expression [22]. Our
current results pose the intriguing possibility that anterior
mammary tumors, such as the original 0_A1 tumor, may
be enriched in cancer stem cells. Previous studies indi-
cated that normal CD24low mammary cells are myoepithe-
lial and have high mammary fat pad reconstitution
capacity, whereas CD24+ population have low capacity for
reconstitution and thus are devoid of normal mammary
stem cells [30]. In addition, a recent report showed thatPage 8 of 12
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Characterization of cancer stem cell markers in Brca1 cell linesFigure 3
Characterization of cancer stem cell markers in Brca1 cell lines. Cell lines A1.1, B1.15, P2.1 and P3.17 were stained 
with fluorescently-conjugated mAb specific to CD44 (A), or CD24 (B), in parallel with isotype control-matched mAb and ana-
lyzed by flow cytometry. In the histograms shown, the thick black line represents positive staining and the gray filled lines rep-
resent the isotype control-matched mAb. (C) Bivariate plots represent the double staining of cell lines with fluorescently-
conjugated CD44 and CD24 mAb. The quadrants are gated based on isotype controls and separate the double positive, single 
positive, and double negative populations. The percent of positive fraction for single label and CD44+/CD24- cells after com-
pensation are indicated in each panel.
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Molecular Cancer 2008, 7:29 http://www.molecular-cancer.com/content/7/1/29freshly isolated normal mammary CD24+ cells have the
capacity to form mammospheres. However, when these
cells are briefly cultured, the CD24- population becomes
enriched in mammosphere-forming and mammary-gland
repopulating cells, indicative of a switch in stem cell pop-
ulation [36]. In our studies, the cell lines derived from the
original 0_A1 mammary tumor, but not cell lines from
posterior tumors contained a population of CD44+/
CD24-/low cells. We recently confirmed that cells express-
ing these markers define a cancer stem cell in Brca1 defi-
cient cell lines [31]. Analysis of additional markers that
distinguish the anterior and posterior Brca1 tumors, and
their capacity for tumor reconstitution need to be per-
formed to test this hypothesis.
Although transplantation preserves gene expression pro-
file of the original Brca1 deficient tumor, it offers only a
limited potential for tumor expansion for further studies
since the starting material is a single mouse tumor. Anal-
ysis of multiple cell lines derived from each one of the
original Brca1 tumors revealed additional characteristics
of these tumors. In spite of changes consistent with expo-
sure to tissue culture conditions and adaptation to growth
as monolayer, such as further loss of basal marker, Cytok-
eratin 5 [37], and gain in expression of Pdgfr α and β, each
group of cell lines segregated with their own tumor of ori-
gin. Cell lines derived from a tumor with EMT features,
0_A1, lost expression of keratins, and contained a distinct
subpopulation of breast cancer stem cells that express
CD44+/CD24- markers [31]. Loss of keratin expression
has been correlated with poor prognosis in human breast
cancer [38]. To our knowledge, the correlation between
enrichment in breast cancer stem cells and EMT features
has not previously been reported. It would be important
to determine whether other BRCA1-deficient human and
mouse tumors with EMT features are enriched in putative
breast cancer stem cells.
Conclusion
Genetic instability associated with BRCA1 deficiency
[28,33,34] is believed to be responsible for therapeutic
failures, but the role of breast cancer stem cells in tumor
progression and drug resistance in this disease are not
known. Heterogeneity of gene expression in tumors origi-
nating from the same Brca1 genetic lesion indicates that
these tumors may have distinct biology and respond dif-
ferently to therapies. Serially transplanted tumors and cell
lines derived from these tumors recapitulate the gene
expression pattern of the tumor of origin and provide
potentially useful tool for preclinical studies in vitro and in
vivo, and studies of Brca1-associted cancer stem cells.
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Heterogeneity of Brca1 tumors. (A) H&E staining of original Brca1 
tumors shows three representative types of morphology. A1 tumor shows 
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epithelial cells with eosinophilic cytoplasm and large leptochromatic 
nuclei. Some cells also form clusters of irregular glands. Several areas have 
whorls and clusters of spindle-shaped tumor cells suggestive of EMT. RP 
tumor shows features of, glandular carcinoma with no evidence of EMT. 
RA tumor has features of squamous nonkeratinizing Carcinoma. This 
tumor also does not show evidence of EMT. (B) Immunofluorescent detec-
tion of vimentin (red) and SMA (green) (right panels) shows mesenchy-
mal features (vimentin) in tumor 0_A1. SMA stains fibroblasts only and 
not tumor cells, and is used here as control.
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